spreads (3).gif

Recall of EpiPen 300 - 20 March 2017

Recall of EpiPen 300 - 20 March 2017

All EpiPens with an April 2017 expiry date are being recalled because of a possible defect that may result in difficulty activating the device in an emergency.

This recall is being conducted by Alphapharm in consultation with the Australian Therapeutic Goods Administration(TGA). Alphapharm Initiates Recall of EpiPen® Auto-Injector in Australia EpiPen® 300 microgram (μg) Adrenaline Injection Syringe Auto-InjectorBatches 5FA665, 5FA6651, 5FA6652, 5FA6653 Alphapharm Pty Ltd, following consultation with the Therapeutic Goods Administration, is recalling the following batches of EpiPen® 300 microgram (μg) Adrenaline Injection Syringe Auto-Injectors due to the potential that these devices may contain a defective part that may result in the device failing to activate or requiring increased force to activate. Batch number Expiry 5FA665 Apr 17 5FA6651 Apr 17 5FA6652 Apr 17 5FA6653 Apr 17

Information provided as per Allergy & Anaphylaxis Australia (A&AA) website media releases More information HERE and HERE

#latest #Community

COMMENTS : Due to the risks associated with comments from unidentified contributors that expose The Beagle to possible legal actions under the NSW Defamation Act 2005 No 77 anonymous or Nom de Plume comments will not be available unless the author is known to the editor by way of a verified email address or by association.

Others who provide their REAL NAME (first name AND Surname) and a verifiable email address (it won't be published) are invited to comment below. (yes it is a pain but please comply - it would be a  shame to see your comment deleted)

Those contributors KNOWN to us and verified may continue to use their First Name or Nom de plume for ease. The primary need for all of this is due to traceability should a legal action arise.

If you need anonymity email us via our normal or encrypted email accounts

Please note that if you are looking for a previous comment that is no longer visible please contact us.